These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10429662)

  • 1. Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells.
    Yamaoka T; Hanada M; Ichii S; Morisada S; Noguchi T; Yanagi Y
    Jpn J Cancer Res; 1999 Jun; 90(6):685-90. PubMed ID: 10429662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.
    Yamaoka T; Hanada M; Ichii S; Morisada S; Noguchi T; Yanagi Y
    Jpn J Cancer Res; 1998 Oct; 89(10):1067-73. PubMed ID: 9849587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin.
    Noguchi T; Ichii S; Morisada S; Yamaoka T; Yanagi Y
    Jpn J Cancer Res; 1998 Oct; 89(10):1061-6. PubMed ID: 9849586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite.
    Noguchi T; Ichii S; Morisada S; Yamaoka T; Yanagi Y
    Jpn J Cancer Res; 1998 Oct; 89(10):1055-60. PubMed ID: 9849585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Profile of the anti-tumor effects of amrubicin, a completely synthetic anthracycline].
    Hanada M; Noguchi T; Murayama T
    Nihon Yakurigaku Zasshi; 2003 Aug; 122(2):141-50. PubMed ID: 12890900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells.
    Hira A; Watanabe H; Maeda Y; Yokoo K; Sanematsu E; Fujii J; Sasaki J; Hamada A; Saito H
    Biochem Pharmacol; 2008 Feb; 75(4):973-80. PubMed ID: 18054347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex.
    Hanada M; Mizuno S; Fukushima A; Saito Y; Noguchi T; Yamaoka T
    Jpn J Cancer Res; 1998 Nov; 89(11):1229-38. PubMed ID: 9914793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amrubicin induces apoptosis in human tumor cells mediated by the activation of caspase-3/7 preceding a loss of mitochondrial membrane potential.
    Hanada M; Noguchi T; Yamaoka T
    Cancer Sci; 2006 Dec; 97(12):1396-403. PubMed ID: 16995876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients.
    Matsunaga Y; Hamada A; Okamoto I; Sasaki J; Moriyama E; Kishi H; Matsumoto M; Hira A; Watanabe H; Saito H
    Ther Drug Monit; 2006 Feb; 28(1):76-82. PubMed ID: 16418698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
    Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.
    Chen N; Chawla SP; Chiorean EG; Read WL; Gorbaty M; Mita AC; Yung L; Bryan P; McNally R; Renschler MF; Sharma S
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):1083-94. PubMed ID: 23400695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.
    Makino Y; Yamamoto N; Sato H; Ando R; Goto Y; Tanai C; Asahina H; Nokihara H; Sekine I; Kunitoh H; Ohe Y; Sugiyama E; Yokote N; Tamura T; Yamamoto H
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):861-9. PubMed ID: 22042514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.
    Okamoto I; Hamada A; Matsunaga Y; Sasaki J; Fujii S; Uramoto H; Yamagata H; Mori I; Kishi H; Semba H; Saito H
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):282-8. PubMed ID: 16028099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer.
    Makino Y; Makihara-Ando R; Ogawa T; Sato H; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Ohe Y; Yamamoto N
    Cancer Sci; 2019 Nov; 110(11):3573-3583. PubMed ID: 31505087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.
    Salvatorelli E; Menna P; Gonzalez Paz O; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
    J Pharmacol Exp Ther; 2012 May; 341(2):474-83. PubMed ID: 22338034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Over-expression of MDR1 in amrubicinol-resistant lung cancer cells.
    Takakuwa O; Oguri T; Ozasa H; Uemura T; Kasai D; Miyazaki M; Maeno K; Sato S
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):669-76. PubMed ID: 21128075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive effects of amrubicin with cisplatin on human lung cancer cell lines.
    Yamauchi S; Kudoh S; Kimura T; Hirata K; Yoshikawa J
    Osaka City Med J; 2002 Jun; 48(1):69-76. PubMed ID: 12375699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxygen radical detoxification enzymes in doxorubicin-sensitive and -resistant P388 murine leukemia cells.
    Ramu A; Cohen L; Glaubiger D
    Cancer Res; 1984 May; 44(5):1976-80. PubMed ID: 6324993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells.
    Ling YH; Priebe W; Perez-Soler R
    Cancer Res; 1993 Apr; 53(8):1845-52. PubMed ID: 8467504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of amrubicin with a 5 day administration schedule in a mouse model].
    Noguchi T; Ichii S; Morisada S; Yamaoka T; Yanagi Y
    Gan To Kagaku Ryoho; 1999 Aug; 26(9):1305-12. PubMed ID: 10478184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.